ResearcherAmsterdam University Medical CentersActive in the last 2 years
Mahrou Vahabi
Matched on OpenAlex author ID A5043933789. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 6
- The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Co-author DOI 10.1016/j.drup.2026.101408↗
- New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/md23080327↗
- Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. Co-author DOI 10.1080/15257770.2024.2319215↗
- Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
- Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10555-023-10127-w↗
- Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in p… Co-author DOI 10.1016/j.semcancer.2023.11.003↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa Giovannetti · 6 shared papers, 2023–2026 · strength 1.50
- Paper The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resista… DOI 10.1016/j.drup.2026.101408↗
- Paper Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor t… DOI 10.1080/15257770.2024.2319215↗
- Paper New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. DOI 10.3390/md23080327↗
- Annalisa Comandatore · 3 shared papers, 2023–2026 · strength 0.71
- Paper The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resista… DOI 10.1016/j.drup.2026.101408↗
- Paper Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker disco… DOI 10.1016/j.semcancer.2023.11.003↗
- Paper Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. DOI 10.1186/s13046-024-03090-z↗
- Luca Morelli · 3 shared papers, 2023–2026 · strength 0.71
- Paper The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resista… DOI 10.1016/j.drup.2026.101408↗
- Paper Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker disco… DOI 10.1016/j.semcancer.2023.11.003↗
- Paper Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. DOI 10.1186/s13046-024-03090-z↗
- Godefridus J. Peters · 2 shared papers, 2023–2024 · strength 0.52
- Paper Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor t… DOI 10.1080/15257770.2024.2319215↗
- Paper Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcino… DOI 10.1007/s10555-023-10127-w↗
- Benoît Immordino · 2 shared papers, 2024–2026 · strength 0.49
- Paper The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resista… DOI 10.1016/j.drup.2026.101408↗
- Paper Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. DOI 10.1186/s13046-024-03090-z↗
- Mafalda Angelica Rocco · 1 shared paper, 2026 · strength 0.33
- Geng Xu · 1 shared paper, 2024 · strength 0.28
- Amir Avan · 1 shared paper, 2024 · strength 0.28
- Daniela Carbone · 1 shared paper, 2025 · strength 0.27
- Camilla Pecoraro · 1 shared paper, 2025 · strength 0.27
- Giulia Lencioni · 1 shared paper, 2025 · strength 0.27
- Barbara Parrino · 1 shared paper, 2025 · strength 0.27
- Patrizia Diana · 1 shared paper, 2025 · strength 0.27
- Giovanni Blandino · 1 shared paper, 2023 · strength 0.22
- Jisce R. Puik · 1 shared paper, 2024 · strength 0.16
- Daniel Liu · 1 shared paper, 2024 · strength 0.16
- Jonathan Krell · 1 shared paper, 2024 · strength 0.16
- Long R. Jiao · 1 shared paper, 2024 · strength 0.16
- Marc G. Besselink · 1 shared paper, 2024 · strength 0.16
- Geert Kazemier M · 1 shared paper, 2024 · strength 0.16
- Rutger‐Jan Swijnenburg · 1 shared paper, 2024 · strength 0.16
- Adam Enver Frampton · 1 shared paper, 2024 · strength 0.16
- Shivan Sivakumar · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.